E-LIB Suche - Ergebnisse für: Pathak, Sanjeev

1

Does Ownership Influence Corporate Social Responsibility (C..:

Pathak, Sanjeev ; Tripathy, Arun Kumar ; Panda, Abinash
Journal of Law and Sustainable Development. 12 (2024) 1 - p. e2417 , 2024

Link: https://doi.org/10.55908..

2

Pimavanserin for psychosis in Parkinson's disease dementia:..:

Weintraub, Daniel ; Espay, Alberto J. ; Sharma, Vibhash D....
Parkinsonism & Related Disorders. 119 (2024) - p. 105951 , 2024

Link: https://doi.org/10.1016/..

3

Challenges and proposed solutions to conducting Alzheimer's..:

Ballard, Clive ; Tariot, Pierre ; Soto-Martin, Maria..
Frontiers in Psychiatry. 15 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

4

Safety Profile of Pimavanserin Therapy in Elderly Patients ..:

Alva, Gus ; Cubała, Wiesław J. ; Berrio, Ana...
Journal of Alzheimer's Disease. 98 (2024) 1 - p. 265-274 , 2024

Link: https://doi.org/10.3233/..

5

Focus on Social and Sustainability Goals: The Blurring Line..:

, In: Digital Economy Post COVID-19 Era; Springer Proceedings in Business and Economics,

Pathak, Sanjeev ; Tripathy, Arun Kumar ; Panda, Abinash - p. 457-465 , 2023

Link: https://doi.org/10.1007/..

6

Safety profile of pimavanserin therapy in elderly patients ..:

Alva, Gustavo ; Cubała, Wiesław J. ; Berrio, Ana...
Alzheimer's & Dementia. 19 (2023) S21 - p. , 2023

Link: https://doi.org/10.1002/..

7

Efficacy and safety of pimavanserin in patients with Alzhei..:

Cummings, Jeffrey ; Devanand, Davangere P ; Ballard, Clive G...
Alzheimer's & Dementia. 18 (2022) S10 - p. , 2022

Link: https://doi.org/10.1002/..

8

Pimavanserin treatment of hallucinations and delusions in p..:

Weintraub, Daniel ; Espay, Alberto ; Sharma, Vibhash...
Neurology. 98 (2022) 18_supplement - p. , 2022

Link: https://doi.org/10.1212/..

9

Renewable Energy Transition for the Himalayan Countries Nep..:

Gulagi, Ashish ; Pathak, Sanjeev ; Bogdanov, Dmitrii.
IEEE Access. 9 (2021) - p. 84520-84544 , 2021

Link: https://doi.org/10.1109/..

10

5 Clinical Evaluation of the Abuse Potential of Buprenorphi..:

Cutler, Andrew J. ; Mathew, Sanjay J. ; DeBakey, Michael E....
CNS Spectrums. 24 (2019) 1 - p. 176-176 , 2019

Link: https://doi.org/10.1017/..

11

Buprenorphine/samidorphan combination for the adjunctive tr..:

Zajecka, John M ; Stanford, Arielle D ; Memisoglu, Asli..
Neuropsychiatric Disease and Treatment. 15 (2019) - p. 795-808 , 2019

Link: https://doi.org/10.2147/..

12

Results from a long-term open-label extension study of adju..:

Thase, Michael E. ; Stanford, Arielle D. ; Memisoglu, Asli...
Neuropsychopharmacology. 44 (2019) 13 - p. 2268-2276 , 2019

Link: https://doi.org/10.1038/..

13

50 Adjunctive Buprenorphine/Samidorphan Combination in Pati..:

Thase, Michael ; Stanford, Arielle D. ; Memisoglu, Asli...
CNS Spectrums. 24 (2019) 1 - p. 203-204 , 2019

Link: https://doi.org/10.1017/..

14

Abuse Potential of Samidorphan: A Phase I, Oxycodone‐, Pent..:

Pathak, Sanjeev ; Vince, Bradley ; Kelsh, Debra...
The Journal of Clinical Pharmacology. 59 (2018) 2 - p. 218-228 , 2018

Link: https://doi.org/10.1002/..

15

S99. Evaluation of Abuse Potential of Samidorphan in Health..:

Setnik, Beatrice ; Nangia, Narinder ; Puhl, Matthew D....
Biological Psychiatry. 83 (2018) 9 - p. S385 , 2018

Link: https://doi.org/10.1016/..